Bioxodes, a Gosselies, Belgium-based biopharmaceutical company which specializes in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, raised €12M in Series A funding.
This financial backing included €8.6M ($9.3M) in capital and €3.4M ($3.7M) in non-dilutive funding from the Wallonia region. It comes on top of the €27M ($29.2M) in capital and subsidies previously raised by Bioxodes, bringing to €39M ($42.2M) the total funding secured by the company since its creation.
The company intends to use the funds to continue clinical development of drug candidate for patients with intracerebral hemorrhage.
Led by CEO Marc Dechamps, and Chief Medical Officer Hans Warrinnier, Bioxodes specializes in the development of therapies for the prevention and treatment of thrombotic and inflammatory diseases. Since its founding in 2013, it has developed its own flagship program based around its Ir-CPI molecule, which is a drug candidate aimed at patients with thromboinflammatory disease.
Ir-CPI is a first-in-class drug candidatem which prevents both the formation of unwanted blood clots and any increased risks of bleeding (action on factors XIa and XIIa). By inhibiting neutrophils activation, it also prevents the acute neuroinflammatory events associated with intracerebral hemorrhage. Derived from a tick’s saliva, this product could become the first injectable antithrombotic drug suitable for use in patients within the first 72 hours of intracerebral hemorrhage.
FinSMEs
21/11/2023